HYDROCHLOROTHIAZIDE; LISINOPRIL | A075776 | CHARTWELL RX SCIENCES LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Premier Consulting FDA-2024-P-3573 · 5 docket documents Premier Consulting filed an amendment to its suitability petition for a Lisinopril and Hydrochlorothiazide oral liquid formulation under ANDA regulations. The petitioner clarified in response to FDA feedback that the proposed dosage form is specifically a "liquid" rather than a solution, suspension, | Suitability | 2024-12-02 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.